Lipella pharmaceuticals announces creation of oral health scientific advisory board

Five-member board will initially focus on the development of lp-310 pittsburgh , march 1, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: lipo) ("lipella" or the "company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a scientific advisory board in oral health.   the five-member board will initially focus on the development of lp-310, lipella's product candidate for the treatment of symptomatic oral lichen planus (olp).
LIPO Ratings Summary
LIPO Quant Ranking